Studies have shown that Infigratinib is effective in treating FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC), gliomas with FGFR1 mutations, and urothelial carcinoma with FGFR1 overexpression [66,67,68]. Here, FGFR1 is linked to central nervous system cancer.